Dr. Julie Gralow Discusses the SWOG S0500 Trial

Dr. Gralow Discusses Toxicities Experienced in the SWOG S0307 TrialПодробнее

Targeted Breast Cancer Treatment, Dr. Julie GralowПодробнее

Dr. Gralow on a Comparison of Toxicities and Patient-Stated Preference in the SWOG S0307 TrialПодробнее

Julie R. Gralow, MD: SWOG SO226 Trial and Bisphosphonates UpdateПодробнее

Dr. Julie Gralow Discusses the Antibody Drug Conjugate T-DM1 for Breast CancerПодробнее

Dr. Julie Gralow: Exercise is MedicineПодробнее

Dr. Julie Gralow Discusses T-DM1-Induced ThrombocytopeniaПодробнее

Dr. Gralow on Future Research Into Bisphosphonates in Breast CancerПодробнее

Dr. Leyland-Jones Discusses the Results of the SWOG S0500 TrialПодробнее

Julie Gralow, MD, provides details on the SWOG S0226 findings presented at SABCS 2020Подробнее

Julie R. Gralow, MD: Cognitive Function and Breast CancerПодробнее

Dr. Julie Gralow on the Importance of Genetic Testing for Breast CancerПодробнее

Julie Gralow, MD, summarizes the RxPONDER trial from the 2020 San Antonio Breast Cancer SymposiumПодробнее

Julie R. Gralow, MD: New Endocrine Therapy For Metastatic Breast CancerПодробнее

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancerПодробнее

Dr. McCormack Gives an Analysis of the SWOG S0500 StudyПодробнее

Dr. Gralow on Adjuvant Bisphosphonates for Breast CancerПодробнее

Julie R. Gralow, MD: The Atlas Trial. Tamoxifen For Five Years or Ten Years?Подробнее

Dr. Julie R. Gralow Discusses Findings from the RxPONDER Study Released at SABCS 2020Подробнее